Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 240 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pneumovax Vaccine Clear all
Recruiting Phase 3 Interventional Accepts healthy volunteers

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

NCT07348692
View directory record Official record
Conditions
Pneumococcal Immunization, Healthy Volunteers
Interventions
PCV21 vaccine, 20vPCV licensed vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
14
States / cities
Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

NCT05084508
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
41
States / cities
Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

NCT00000829
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine

NCT00589394
View directory record Official record
Conditions
Healthy
Interventions
pneumococcal vaccination (Pneumovax)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 12, 2026, 2:41 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

NCT07086677
View directory record Official record
Conditions
Streptococcus Pneumoniae
Interventions
PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 84 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
20
States / cities
Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older

NCT00741039
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
inactivated influenza vaccine and the 23- valent pneumococcal vaccine, inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 12, 2026, 2:41 AM EDT
Recruiting No phase listed Observational

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941
View directory record Official record
Conditions
Pneumonia
Interventions
Diagnostic test on urine samples
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
12,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
40
States / cities
El Centro, California • Fontana, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 12, 2026, 2:41 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

NCT07629440
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 211 Days
Enrollment
3,230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
106
States / cities
Bessemer, Alabama • Birmingham, Alabama • Centreville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

NCT05879107
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, PCV20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
1,113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
20
States / cities
Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

NCT05158140
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V110, V114, mRNA-1273, Placebo for V110, Placebo for V114
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
42
States / cities
North Hollywood, California • Northridge, California • Paramount, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 12, 2026, 2:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage

NCT01109108
View directory record Official record
Conditions
Nasopharyngeal Carriage of S. Pneumoniae
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
9,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

NCT04168190
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, Pneumovax™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
20
States / cities
Birmingham, Alabama • Mesa, Arizona • Coral Gables, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

NCT01681992
View directory record Official record
Conditions
Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
4,538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

NCT00574548
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
13 valent Pneumococcal Conjugate Vaccine, 23-valent Pneumococcal Polysaccharide Vaccine
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
6
States / cities
Chandler, Arizona • Pembroke Pines, Florida • Boise, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 12, 2026, 2:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

NCT01128426
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
No Intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
2 Months to 3 Years
Enrollment
53,902 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

NCT05028634
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

9-valent CRM 197 Pneumococcal

NCT00133549
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
Placebo, PNU-IMUNE®23, Nine-valent pneumococcal conjugate (PNCRM9)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
2
States / cities
Rochester, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

NCT01359150
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 12, 2026, 2:41 AM EDT
Recruiting Phase 2 Interventional

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

NCT02232191
View directory record Official record
Conditions
Asplenia
Interventions
Pneumovax-23
Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 12, 2026, 2:41 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

NCT03550313
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mobile, Alabama • Harrisburg, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
4,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 12, 2026, 2:41 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06736041
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,714 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
66
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 12, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

NCT05412030
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
AFX3772, Prevnar 13, Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
42 Days to 90 Days
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
48
States / cities
Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 12, 2026, 2:41 AM EDT